Press Room

Press Clipping / Feb 17, 2022

Seven Companies in Ireland achieve the Business Working Responsibly mark with a further ten recertifying to the standard

BITCI Ireland, 17 February 2022

Business Working Responsibility Mark logo | Hovione
  • The Mark is operated by Business in the Community Ireland (BITCI), the non-profit organisation dedicated to sustainability and third-party audited by the National Standards Authority of Ireland (NSAI).
  • Seven companies achieved the Mark for the first time with another ten achieving recertification.


Press Release Thursday 17th February:  Over 200 business leaders attended Business in the Community Ireland’s virtual celebration event where the latest companies certified to the Business Working Responsibly mark in 2021/2022 were announced.

The Mark which is run by Business in the Community Ireland and based on ISO 26000 is valid for three years and is independently audited by the National Standards Authority of Ireland (NSAI).

Seven companies are being accredited to the Mark for the first time this year and they are Alkermes, An Post, Grant Thornton Ireland, Iarnród Éireann – Irish Rail, Ornua, Vermilion and William Fry.

In addition, ten companies achieved recertification to the Mark and they are Boots (Retail) Ireland Ltd, BT Ireland, Central Bank of Ireland, CRH Operating Companies in Ireland, Deloitte Ireland, Gas Networks Ireland, HEINEKEN Ireland, Hovione, Intel Ireland and Sodexo Ireland. 46 companies in Ireland have now achieved the sustainability standard.

The Mark  looks at leadership, policies, practices, performance and impact in areas such as employee wellbeing, diversity and inclusion, environmental practices, supply chain management and engagement with the local community.

For more details on our sustainability standard, visit the Business Working Responsibly mark section of our website. 


Read the full article on



Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at  


Continuous Tableting and the Road to Global Adoption

Mar 04, 2024